However, when treated with Guttiferone K, the c-MYC protein was degraded by the stabilization of FBXW7, and cell cycle re-entry was hindered in prostate cancer cells, suggesting that manipulating the protein levels of MYC could further regulate the quiescent-to-proliferative switch [83,84]. The gene discussed is MYC; the disease is prostate carcinoma.